Viking Therapeutics Inc [NASDAQ: VKTX] gained 1.34% on the last trading session, reaching $24.14 price per share at the time. The company report on January 31, 2024 at 4:05 PM that Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024.
Conference Call Scheduled for Wednesday, February 7 at 4:30 p.m. Eastern Time.
Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2023 after the market close on Wednesday, February 7, 2024.
If compared to the average trading volume of 2.58M shares, VKTX reached a trading volume of 4020301 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Viking Therapeutics Inc [VKTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VKTX shares is $34.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VKTX stock is a recommendation set at 1.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
ROTH MKM have made an estimate for Viking Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 31, 2023.
The Average True Range (ATR) for Viking Therapeutics Inc is set at 1.51 The Price to Book ratio for the last quarter was 6.56, with the Price to Cash per share for the same quarter was set at 3.76.
Trading performance analysis for VKTX stock
Viking Therapeutics Inc [VKTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.54. With this latest performance, VKTX shares gained by 29.72% in over the last four-week period, additionally plugging by 70.48% over the last 6 months – not to mention a rise of 186.36% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VKTX stock in for the last two-week period is set at 68.35, with the RSI for the last a single of trading hit 70.12, and the three-weeks RSI is set at 67.38 for Viking Therapeutics Inc [VKTX]. The present Moving Average for the last 50 days of trading for this stock 18.27, while it was recorded at 22.95 for the last single week of trading, and 16.56 for the last 200 days.
Viking Therapeutics Inc [VKTX]: A deeper dive into fundamental analysis
Viking Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 28.44 and a Current Ratio set at 28.44.
Viking Therapeutics Inc [VKTX]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Viking Therapeutics Inc posted -0.26/share EPS, while the average EPS was predicted by analysts to be reported at -0.23/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -13.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VKTX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Viking Therapeutics Inc go to 40.00%.
An analysis of Institutional ownership at Viking Therapeutics Inc [VKTX]
The top three institutional holders of VKTX stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in VKTX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in VKTX stock with ownership which is approximately 5.8325%.
